Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov ID: NCT01383928

Public ClinicalTrials.gov record NCT01383928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of IXAZOMIB (MLN9708), Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Study identification

NCT ID
NCT01383928
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Enrollment
64 participants

Conditions and interventions

Interventions

  • Ixazomib Drug
  • Lenalidomide Drug
  • Dexamethasone Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 30, 2011
Primary completion
Oct 12, 2014
Completion
Nov 26, 2017
Last update posted
Mar 20, 2019

2011 – 2017

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
UCSF Medical Center Berkeley California 94704
City of Hope National Medical Center Duarte California 91010
Stanford University Stanford California 94305
H Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612
University of Chicago Medical Center Chicago Illinois 60637
Associates of Oncology/Hematology PC Rockville Maryland 20850
Dana Farber Cancer Institute Boston Massachusetts 02115
University of Michigan Ann Arbor Michigan 48109
Michigan State University Lansing Michigan 48910
Hackensack University Medical Center Hackensack New Jersey 07601
Memorial Sloan Kettering Cancer Center New York New York 10021
Mount Sinai Hospital New York New York 31406
Duke University Medical Center Durham North Carolina 27705
Ohio State University Columbus Ohio 43210
Mercy St Anne Hospital Toledo Ohio 43623
Oregon Health and Science University Portland Oregon 97239
SCRI Tennessee Oncology Nashville Nashville Tennessee 37203
Baylor Sammons Cancer Center Dallas Texas 75246
Virginia Cancer Care Specialist Fairfax Virginia 22031
Virginia Cancer Specialists PC Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01383928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 20, 2019 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01383928 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →